Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 7-(2-(2-amino-4-thiazolyl)-4-carboxy-2-butenoylamino)-3-cephem-4-carboxylic Acid
2. 7432 S
3. 7432-s
4. Cedax
5. Sch 39720
6. Sch-39720
7. Sch39720
1. 97519-39-6
2. Cedax
3. Ceftibuteno
4. Ceftibutenum
5. Ceftibutene
6. Sch 39720
7. Ceftibuten Hydrate
8. Cis-ceftibuten
9. Sch-39720
10. 7432-s
11. Antibiotic 7432s
12. Nsc-758925
13. Achn383
14. Achn-383
15. Chebi:3510
16. Iw71n46b4y
17. (+)-(6r,7r)-7-((z)-2-(2-amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid
18. Ceftibuten Dihydrate
19. Cis-ceftibutin
20. 97519-39-6 (free)
21. Isocef
22. Cetb
23. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 7-((2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl)amino)-8-oxo-, (6r-(6alpha,7beta(z)))-
24. Cephalosporin 7432-s
25. (6r,7r)-7-[[(z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
26. (6r,7r)-7-((z)-2-(2-aminothiazol-4-yl)-4-carboxybut-2-enamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
27. Ceftibutene [inn-french]
28. Ceftibutenum [inn-latin]
29. Ceftibuteno [inn-spanish]
30. Unii-iw71n46b4y
31. Ceftibutin
32. Ceprifran
33. Ceftem
34. Keimax
35. Ceftibuten [usan:inn:ban]
36. S 7432
37. Ncgc00095137-01
38. Ceftibuten-13c3
39. Ceftibuten, 95%
40. Mfcd00864918
41. Ceftibuten [mi]
42. Ceftibuten [inn]
43. Ceftibuten (usan/inn)
44. Spectrum5_001558
45. Ceftibuten [usan]
46. Ceftibuten [vandf]
47. Ceftibutin [vandf]
48. Ceftibuten [who-dd]
49. Chembl1605
50. Dsstox_cid_25925
51. Dsstox_rid_81227
52. Dsstox_gsid_45925
53. Schembl37054
54. Bspbio_002733
55. Spectrum1505207
56. Dtxsid4045925
57. Gtpl12029
58. Hms1922l17
59. Hms2093k18
60. Hms3715p10
61. Pharmakon1600-01505207
62. Hy-b0698
63. Zinc3871967
64. Tox21_111446
65. Bdbm50370586
66. Ccg-39440
67. Nsc758925
68. Akos005146205
69. Akos015854930
70. Db01415
71. Nsc 758925
72. Ncgc00178501-01
73. Ncgc00178501-04
74. Sbi-0206740.p001
75. Cas-97519-39-6
76. C-2550
77. C08117
78. D00922
79. Ab01563048_01
80. 519c396
81. Ceftibuten, Antibiotic For Culture Media Use Only
82. Q419521
83. Sr-05000001989
84. Sr-05000001989-1
85. 7-[2-(2-amino-1,3-thiazol-4-yl)-4-carboxyisocrotonamide]-3-cephem-4-carboxylicacid
86. (6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
87. (6r,7r)-7-[[(2z)-2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-buten-1-yl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
88. (6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
89. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 7-((2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl)amino)-8-oxo-, (6r-(6.alpha.,7.beta.(z)))-
90. 7beta-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-3,4-didehydrocepham-4-carboxylic Acid
| Molecular Weight | 410.4 g/mol |
|---|---|
| Molecular Formula | C15H14N4O6S2 |
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 6 |
| Exact Mass | 410.03547653 g/mol |
| Monoisotopic Mass | 410.03547653 g/mol |
| Topological Polar Surface Area | 217 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 755 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Cedax |
| PubMed Health | Ceftibuten (By mouth) |
| Drug Classes | Antibiotic |
| Drug Label | CEDAX (ceftibuten capsules) and (ceftibuten for oral suspension) contain the active ingredient ceftibuten as ceftibuten dihydrate. Ceftibuten dihydrate is a semisynthetic cephalosporin antibiotic for oral administration. Chemically, it is (+)-(6R,7R)... |
| Active Ingredient | Ceftibuten dihydrate |
| Dosage Form | Capsule; For suspension |
| Route | Oral |
| Strength | eq 180mg base/5ml; eq 90mg base/5ml; eq 400mg base |
| Market Status | Prescription |
| Company | Pernix Therap |
| 2 of 2 | |
|---|---|
| Drug Name | Cedax |
| PubMed Health | Ceftibuten (By mouth) |
| Drug Classes | Antibiotic |
| Drug Label | CEDAX (ceftibuten capsules) and (ceftibuten for oral suspension) contain the active ingredient ceftibuten as ceftibuten dihydrate. Ceftibuten dihydrate is a semisynthetic cephalosporin antibiotic for oral administration. Chemically, it is (+)-(6R,7R)... |
| Active Ingredient | Ceftibuten dihydrate |
| Dosage Form | Capsule; For suspension |
| Route | Oral |
| Strength | eq 180mg base/5ml; eq 90mg base/5ml; eq 400mg base |
| Market Status | Prescription |
| Company | Pernix Therap |
Indicated for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.
Ceftibuten is an antibiotic with bactericidal actions.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01D - Other beta-lactam antibacterials
J01DD - Third-generation cephalosporins
J01DD14 - Ceftibuten
Absorption
Rapidly absorbed following oral administration.
Route of Elimination
Ceftibuten is excreted in the urine; 95% of the administered radioactivity was recovered either in urine or feces.
Volume of Distribution
0.21 L/kg [adult subjects]
0.5 L/kg [fasting pediatric patients]
A study with radiolabeled ceftibuten administered to 6 healthy adult male volunteers demonstrated that cis-ceftibuten is the predominant component in both plasma and urine. About 10% of ceftibuten is converted to the trans-isomer is approximately 1/8 as antimicrobially potent as the cis-isomer.
Ceftibuten exerts its bactericidal action by binding to essential target proteins of the bacterial cell wall. This binding leads to inhibition of cell-wall synthesis.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A CAS-97519-39-6 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CAS-97519-39-6, including repackagers and relabelers. The FDA regulates CAS-97519-39-6 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CAS-97519-39-6 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CAS-97519-39-6 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CAS-97519-39-6 supplier is an individual or a company that provides CAS-97519-39-6 active pharmaceutical ingredient (API) or CAS-97519-39-6 finished formulations upon request. The CAS-97519-39-6 suppliers may include CAS-97519-39-6 API manufacturers, exporters, distributors and traders.
click here to find a list of CAS-97519-39-6 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CAS-97519-39-6 DMF (Drug Master File) is a document detailing the whole manufacturing process of CAS-97519-39-6 active pharmaceutical ingredient (API) in detail. Different forms of CAS-97519-39-6 DMFs exist exist since differing nations have different regulations, such as CAS-97519-39-6 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CAS-97519-39-6 DMF submitted to regulatory agencies in the US is known as a USDMF. CAS-97519-39-6 USDMF includes data on CAS-97519-39-6's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CAS-97519-39-6 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CAS-97519-39-6 suppliers with USDMF on PharmaCompass.
A CAS-97519-39-6 written confirmation (CAS-97519-39-6 WC) is an official document issued by a regulatory agency to a CAS-97519-39-6 manufacturer, verifying that the manufacturing facility of a CAS-97519-39-6 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting CAS-97519-39-6 APIs or CAS-97519-39-6 finished pharmaceutical products to another nation, regulatory agencies frequently require a CAS-97519-39-6 WC (written confirmation) as part of the regulatory process.
click here to find a list of CAS-97519-39-6 suppliers with Written Confirmation (WC) on PharmaCompass.
CAS-97519-39-6 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CAS-97519-39-6 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CAS-97519-39-6 GMP manufacturer or CAS-97519-39-6 GMP API supplier for your needs.
A CAS-97519-39-6 CoA (Certificate of Analysis) is a formal document that attests to CAS-97519-39-6's compliance with CAS-97519-39-6 specifications and serves as a tool for batch-level quality control.
CAS-97519-39-6 CoA mostly includes findings from lab analyses of a specific batch. For each CAS-97519-39-6 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CAS-97519-39-6 may be tested according to a variety of international standards, such as European Pharmacopoeia (CAS-97519-39-6 EP), CAS-97519-39-6 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CAS-97519-39-6 USP).
LOOKING FOR A SUPPLIER?
